NASDAQ:AVRO - Avrobio Stock Price, Forecast & News

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

Avrobio Inc (NASDAQ:AVRO) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.57) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.02. View Avrobio's Earnings History.

Avrobio is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Avrobio.

6 analysts have issued 12-month price targets for Avrobio's shares. Their forecasts range from $24.42 to $43.00. On average, they anticipate Avrobio's share price to reach $33.08 in the next twelve months. This suggests a possible upside of 45.2% from the stock's current price. View Analyst Price Targets for Avrobio.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avrobio.

News stories about AVRO stock have trended positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avrobio earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Avrobio.

Avrobio saw a decrease in short interest in December. As of December 31st, there was short interest totalling 1,610,000 shares, a decrease of 8.5% from the December 15th total of 1,760,000 shares. Based on an average trading volume of 189,600 shares, the days-to-cover ratio is presently 8.5 days. Currently, 7.2% of the company's stock are sold short. View Avrobio's Current Options Chain.

Some companies that are related to Avrobio include Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Regenxbio (RGNX), Cortexyme (CRTX), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Alector (ALEC), Orchard Therapeutics (ORTX), Coherus Biosciences (CHRS), DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG), Aerie Pharmaceuticals (AERI), Sangamo Therapeutics (SGMO) and Mesoblast (MESO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Avrobio investors own include Exelixis (EXEL), Biohaven Pharmaceutical (BHVN), Aerie Pharmaceuticals (AERI), Arrowhead Pharmaceuticals (ARWR), Axsome Therapeutics (AXSM), Cronos Group (CRON), Dicerna Pharmaceuticals (DRNA), Fate Therapeutics (FATE), Amicus Therapeutics (FOLD) and Uniqure (QURE).

(AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

Avrobio's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Nisa Investment Advisors LLC (0.08%). Company insiders that own Avrobio stock include Bruce Booth, Christopher Paige and Geoffrey Mackay. View Institutional Ownership Trends for Avrobio.

AVRO stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. View Insider Buying and Selling for Avrobio.

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AVRO stock can currently be purchased for approximately $22.78.

Avrobio has a market capitalization of $721.44 million. The company earns $-46,360,000.00 in net income (profit) each year or ($3.62) on an earnings per share basis. Avrobio employs 49 workers across the globe.View Additional Information About Avrobio.

The official website for Avrobio is http://www.avrobio.com/.

Avrobio's mailing address is ONE KENDALL SQUARE BLDG. 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]